Artiva Biotherapeutics announced the appointment of Thad Huston as its new Chief Financial Officer. Huston brings more than 30 years of global leadership experience in finance, commercial strategy, and operations across the pharmaceutical, biotechnology, and medical device sectors. He most recently served as CFO and COO of Galapagos, where he helped steer the company’s transition into a cell‑therapy platform before departing on August 1 2025. Prior to Huston, Artiva’s CFO was Neha Krishnamohan, who had overseen the company’s early‑stage financial operations.
In his new role, Huston will oversee Artiva’s financial reporting, investor relations, and strategic planning. He is expected to strengthen the company’s capital allocation discipline and scale commercial operations as Artiva advances its AlloNK platform in autoimmune indications. The appointment signals Artiva’s intent to build a robust finance function that can support the company’s clinical milestones and prepare for potential commercialization.
Artiva’s financial context underscores the importance of the new CFO. The company’s revenue declined in 2024, and it remains unprofitable, with a cash runway that extends into the second quarter of 2027. As of September 30 2025, Artiva held $123 million in cash, cash equivalents, and investments. Huston’s experience in managing cash burn and securing funding will be critical as the company continues to invest in clinical development and seeks additional capital to sustain its pipeline.
The board approved an inducement grant of 220,000 restricted stock units for Huston, vesting over four years. The grant is contingent on the filing of a registration statement on Form S‑8 to register the shares issuable under the Inducement Plan. This move reflects Artiva’s commitment to aligning executive incentives with long‑term shareholder value.
AlloNK, Artiva’s lead product candidate, is an allogeneic, off‑the‑shelf NK cell therapy that enhances antibody‑dependent cellular cytotoxicity. The platform has received FDA Fast Track designation for refractory rheumatoid arthritis, positioning it as a promising treatment for autoimmune diseases. By appointing a seasoned finance executive, Artiva aims to ensure that its financial strategy is aligned with the clinical and regulatory milestones that will ultimately determine the commercial viability of AlloNK.
Overall, the CFO appointment is a strategic step to reinforce Artiva’s financial discipline and operational execution as it navigates the critical phases of clinical development and prepares for future funding rounds. The addition of Huston’s expertise is expected to support the company’s growth trajectory and strengthen investor confidence in its long‑term plans.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.